Gilead Sciences gains EU approval for Trodelvy in first-line metastatic TNBC
Gilead Sciences (NASDAQ:GILD) announced that the European Commission has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) as monotherapy for adult patients with unresectable or metastatic triple-negative breast cancer who have not received prior systemic therapy and are not candidates for PD-1 or PD-L1 inhibitor treatment.


-640x360.webp&w=3840&q=75)
_1426541_640x360_2504457283821-640x360.webp&w=3840&q=75)

_1426534_640x360_2504460355645-640x360.webp&w=3840&q=75)


_1426527_640x360_2504459843611-640x360.webp&w=3840&q=75)


